Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.7K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.7K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K
Tumor Immunotherapy01:27

Tumor Immunotherapy

538
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
538

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

mTORC1-independent IgA production: a unique pathway for gut immune homeostasis.

International immunology·2025
Same author

Role of Group 2 innate lymphoid cells in intranasal sensitization-induced allergic rhinitis in mice.

International immunology·2025
Same author

The role of IL-4+ memory T cells in SARS-CoV-2 booster vaccination.

International immunology·2025
Same author

An interorgan neuroimmune circuit promotes visceral hypersensitivity.

Research square·2025
Same author

Chromosomal Instability Is Associated with cGAS-STING Activation in EGFR-TKI Refractory Non-Small-Cell Lung Cancer.

Cells·2025
Same author

Single-cell multiomic analysis revealed the differentiation, localization, and heterogeneity of IL10+ Foxp3- follicular T cells in humans.

International immunology·2025

Related Experiment Video

Updated: Jul 12, 2025

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics
06:00

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics

Published on: May 14, 2016

11.1K

BCL6 fine-tunes long-term tumor control.

Shiki Takamura1, Aneela Nomura1, Masato Kubo2

  • 1Laboratory for Immunological Memory, IMS RIKEN Center for Integrative Medical Science, Yokohama, Japan.

Science Immunology
|October 20, 2023
PubMed
Summary

The transcription factor BCL6 acts as a crucial gatekeeper for CD8+ progenitor cells within tumors. It prevents their over-differentiation, maintaining a stem-like population for sustained tumor control.

More Related Videos

In Vitro Differentiation Model of Human Normal Memory B Cells to Long-lived Plasma Cells
10:26

In Vitro Differentiation Model of Human Normal Memory B Cells to Long-lived Plasma Cells

Published on: January 20, 2019

12.2K
Ex vivo Expansion of Tumor-reactive T Cells by Means of Bryostatin 1/Ionomycin and the Common Gamma Chain Cytokines Formulation
07:20

Ex vivo Expansion of Tumor-reactive T Cells by Means of Bryostatin 1/Ionomycin and the Common Gamma Chain Cytokines Formulation

Published on: January 14, 2011

14.8K

Related Experiment Videos

Last Updated: Jul 12, 2025

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics
06:00

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics

Published on: May 14, 2016

11.1K
In Vitro Differentiation Model of Human Normal Memory B Cells to Long-lived Plasma Cells
10:26

In Vitro Differentiation Model of Human Normal Memory B Cells to Long-lived Plasma Cells

Published on: January 20, 2019

12.2K
Ex vivo Expansion of Tumor-reactive T Cells by Means of Bryostatin 1/Ionomycin and the Common Gamma Chain Cytokines Formulation
07:20

Ex vivo Expansion of Tumor-reactive T Cells by Means of Bryostatin 1/Ionomycin and the Common Gamma Chain Cytokines Formulation

Published on: January 14, 2011

14.8K

Area of Science:

  • Immunology
  • Cancer Biology
  • Molecular Biology

Background:

  • CD8+ T cells are critical for anti-tumor immunity.
  • Tumor microenvironments can impair T cell function.
  • Maintaining a pool of functional T cells is essential for long-term cancer control.

Purpose of the Study:

  • To investigate the role of the transcription factor BCL6 in regulating CD8+ progenitor cell function within tumors.
  • To understand how BCL6 influences T cell differentiation and persistence in the tumor microenvironment.

Main Methods:

  • Analysis of transcription factor BCL6 expression in tumor-infiltrating CD8+ T cells.
  • Assessment of CD8+ progenitor cell differentiation status.
  • Evaluation of the impact of BCL6 on T cell stem-like properties and tumor control.

Main Results:

  • BCL6 acts as a gatekeeper, controlling the differentiation of CD8+ progenitor cells in tumors.
  • BCL6 prevents the excessive terminal differentiation of these cells.
  • Preservation of stem-like CD8+ progenitor cells by BCL6 contributes to long-term tumor control.

Conclusions:

  • The transcription factor BCL6 is essential for maintaining functional CD8+ progenitor cells in tumors.
  • BCL6's gatekeeper function is critical for sustaining anti-tumor immunity and improving long-term tumor control.